title: Ultrasonic analysis of anthracycline-induced myocardial damage using cyclic variation of integrated backscatter.
abstract: To test the feasibility of integrated backscatter (IB) for detecting anthracycline cardiotoxicity, we performed conventional echocardiography and IB analysis. For interindividual comparison, 32 patients with non-Hodgkin's lymphoma and 14 control subjects were selected. Of the patients, 10 had been treated with doxorubicin doses of </=200 mg/m(2) (low dose), 15 with </=400 mg/m(2) (moderate dose), and 7 with >400 mg/m(2) (high dose). In intraindividual comparison, 8 patients were examined before doxorubicin therapy and at a dose of 100 mg/m(2) and 8 were examined before and at a 300-mg/m(2) dose. Cyclic variation of IB (CV-IB) was obtained at the left ventricular posterior wall, using a modified, commercially available system in M-mode format. In interindividual comparison, CV-IB in high- and moderate-dose groups was smaller. In intraindividual comparison, CV-IB decreased after treatment with 300 mg/m(2) of doxorubicin. CV-IB was affected in some patients treated with a moderate dose of doxorubicin. IB analysis may be helpful for detecting early anthracycline cardiotoxicity.
authors.affiliation: Department of Cardiology, Kanazawa Red Cross Hospital, Minma 2-251, Kanazawa 921-8162, Japan. hidnagai@ybb.ne.jp
authors.forename: Hideo
authors.initials: H
authors.lastname: Nagai
authors.forename: Wataru
authors.initials: W
authors.lastname: Omi
authors.forename: Toyoshi
authors.initials: T
authors.lastname: Yuasa
authors.forename: Satoru
authors.initials: S
authors.lastname: Sakagami
authors.forename: Shigeo
authors.initials: S
authors.lastname: Takata
authors.forename: Kenichi
authors.initials: K
authors.lastname: Kobayashi
mesh_terms: D000328:Adult; D000368:Aged; D018943:Anthracyclines / Q000008:administration & dosage / Q000009:adverse effects*; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage / Q000009:adverse effects; D009202:Cardiomyopathies / Q000139:chemically induced* / Q000000981:diagnostic imaging* / Q000503:physiopathology; D003971:Diastole / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects; D004452:Echocardiography; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006352:Heart Ventricles / Q000187:drug effects / Q000503:physiopathology; D019337:Hematologic Neoplasms / Q000150:complications / Q000188:drug therapy / Q000503:physiopathology; D006801:Humans; D007564:Japan; D008228:Lymphoma, Non-Hodgkin / Q000150:complications / Q000188:drug therapy / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D013318:Stroke Volume / Q000187:drug effects; D013599:Systole / Q000187:drug effects
chemical_list: D018943:Anthracyclines; D000903:Antibiotics, Antineoplastic; D004317:Doxorubicin